Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 72% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- Strong ROE of 66.1% with 84.3% net margin
- Revenue growing at 87% annually
TG Therapeutics, Inc. - Common Stock (TGTX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $4.3 billion . Key value metrics: P/E ratio 10.1, P/B ratio 6.64, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
TG Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
TG Therapeutics, Inc. - Common Stock (TGTX) is currently trading 72% above its Graham Number of $15.64, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a low trailing P/E ratio of 10.1x.
On financial health, TGTX shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and strong return on equity of 66.1% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.38.
StockPik's composite Value Score for TGTX is 77/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
TGTX reports a high gross margin of 85.8% (sector average: 33.5%) and a solid operating margin of 16.8%.
TGTX shows revenue growing at 87% year-over-year, with earnings growing at 1,812%.